November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at email@example.com)
July 29, 2016
Russian Federal Customs Service does not confirm reports on resumption of investigative procedures
Quotations for Russian Eurobonds in US dollars
Quotations for Russian Eurobonds in euros and rubles
Russian Foreign Ministry working to prepare new ministerial meeting in Normandy Format - Deputy Foreign Minister Karasin
GAZPROM NEFT'S NET PROFIT TO RAS UP 11% IN H1 TO 79.2 BLN RUBLES - COMPANY
Iran received proposals from Lukoil on Anaran project, ready for discussion (Part 2)
Ukraine's Rada calls on Kyiv not to give agreement to new Russian ambassador
Novak notes progress in settling Belarusian debt for gas (Part 2)
Moscow interbank Ruonia rate and volume of the transactions used to calculate the rate
Mosenergo posts RAS net profit of 10.2 bln rubles in H1; EBITDA - 20.8 bln rubles
RUSSIAN FOREIGN MINISTRY WORKING ON NEW MINISTERIAL MEETING IN NORMANDY FORMAT - RUSSIAN DEPUTY FOREIGN MINISTER KARASIN
Moscow, Ankara plan to resume inter-parliamentary contacts - State Duma Committee on International Affairs
PhosAgro shareholders approve 63 rubles per share in dividends for Q1
Over 170 participants in illegal armed units detained in Northern Caucasus Federal District in January-June 2016